Revisiting Roles of Health Technology Assessment on Drug Policy in Universal Health Coverage in Thailand: Where Are We? And What Is Next?

被引:10
|
作者
Tanvejsilp, Pimwara [1 ]
Taychakhoonavudh, Suthira [2 ]
Chaikledkaew, Usa [3 ,4 ]
Chaiyakunapruk, Nathorn [5 ,6 ,7 ,8 ]
Ngorsuraches, Surachat [9 ]
机构
[1] Prince Songkla Univ, Fac Pharmaceut Sci, Dept Pharm Adm, Hat Yai, Songkhla, Thailand
[2] Chulalongkorn Univ, Fac Pharmaceut Sci, Bangkok, Thailand
[3] Mahidol Univ, Fac Pharm, Dept Pharm, Social Adm Pharm Excellence Res Unit, Bangkok, Thailand
[4] Mahidol Univ, Hlth Technol Assessment Postgrad Program, Bangkok, Thailand
[5] Monash Univ Malaysia, Sch Pharm, Subang Jaya, Selangor, Malaysia
[6] Naresuan Univ, Fac Pharmaceut Sci, Ctr Pharmaceut Outcomes Res, Dept Pharm Practice, Phitsanulok, Thailand
[7] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA
[8] Monash Univ Malaysia, Asian Ctr Evidence Synth Populat Implementat & Cl, Hlth & Well Being Cluster, Global Asia 21st Century Platform, Subang Jaya, Selangor, Malaysia
[9] Auburn Univ, Dept Hlth Outcomes Res & Policy, Harrison Sch Pharm, 037 James E Foy Hall, Auburn, AL 36849 USA
关键词
drug policy; health technology assessment; Thailand; universal health coverage;
D O I
10.1016/j.vhri.2018.11.004
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: To describe the process, challenges, and future direction of health technology assessment (HTA), focusing on the drug selection of the National List of Essential Medicines (NLEM) in Thailand. Methods: Literature and government documents were reviewed and analyzed by authors with experiences in HTA and drug policy in the country. Results: The structure of HTA and its process in the drug selection of the NLEM were described, followed by the outcomes of the use of HTA. Examples of lowering drug prices, as a result of price negotiation using HTA, were presented. A few examples were also provided to demonstrate how decisions were made from considering factors beyond cost-effectiveness findings. Finally, challenges on various issues including improvement of HTA structure and process were discussed for the future direction of HTA in Thailand. Conclusions: HTA has been adopted as a tool for the drug selection of the NLEM to help Thailand achieve universal health coverage. Nevertheless, various challenge sexist and need to be addressed.
引用
收藏
页码:78 / 82
页数:5
相关论文
共 50 条
  • [21] Health technology assessment and priority setting for universal health coverage: a qualitative study of stakeholders’ capacity, needs, policy areas of demand and perspectives in Nigeria
    Benjamin S. C. Uzochukwu
    Chinyere Okeke
    Niki O’Brien
    Francis Ruiz
    Issiaka Sombie
    Samantha Hollingworth
    Globalization and Health, 16
  • [22] Health Technology Assessment and Its Use in Drug Policy in Malaysia
    Shafie, Asrul Akmal
    Chandriah, Haarathi
    Yong, Yee Vern
    Puteh, Sharifa Ezat Wan
    VALUE IN HEALTH REGIONAL ISSUES, 2019, 18 : 145 - 150
  • [23] NIGERIA'S NATIONAL HEALTH ACT, NATIONAL HEALTH INSURANCE SCHEME ACT AND NATIONAL HEALTH POLICY: A RECIPE FOR UNIVERSAL HEALTH COVERAGE OR WHAT?
    Nnamuchi, Obiajulu
    Nwatu, Samuel
    Anozie, Miriam
    Onyeabor, Emmanuel
    MEDICINE AND LAW, 2018, 37 (04): : 645 - 681
  • [24] Importance of Evidence-Based Health Insurance Reimbursement and Health Technology Assessment for Achieving Universal Health Coverage and Improved Access to Health in India
    Dang, Amit
    Dang, Dimple
    Vallish, B. N.
    VALUE IN HEALTH REGIONAL ISSUES, 2021, 24 : 24 - 30
  • [25] Health technology assessment in oncology - what is it and why do we need it?
    Woods, K
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 19 - 19
  • [26] Universal Health Coverage in Francophone Sub-Saharan Africa: Assessment of Global Health Experts' Confidence in Policy Options
    Paul, Elisabeth
    Fecher, Fabienne
    Meloni, Remo
    van Lerberghe, Wim
    GLOBAL HEALTH-SCIENCE AND PRACTICE, 2018, 6 (02): : 260 - 271
  • [27] What Is Next for Patient Preferences in Health Technology Assessment? A Systematic Review of the Challenges
    Huls, Samare P. I.
    Whichello, Chiara L.
    van Exel, Job
    Uyl-de Groot, Carin A.
    de Bekker-Grob, Esther W.
    VALUE IN HEALTH, 2019, 22 (11) : 1318 - 1328
  • [28] Ethical and Social Values for Paediatric Health Technology Assessment and Drug Policy
    Denburg, Avram E.
    Giacomini, Mita
    Ungar, Wendy
    Abelson, Julia
    INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2022, 11 (03) : 374 - 382
  • [29] Addressing Challenges in Health Technology Assessment Institutionalization for Furtherance of Universal Health Coverage Through South-South Knowledge Exchange: Lessons From Bhutan, Kenya, Thailand, and Zambia
    Kim, Taeyoung
    Sharma, Manushi
    Teerawattananon, Yot
    Oh, Cecilia
    Ong, Leslie
    Hangoma, Peter
    Adhikari, Deepika
    Pempa, Pempa
    Kairu, Angela
    Orangi, Stacey
    Dabak, Saudamini Vishwanath
    VALUE IN HEALTH REGIONAL ISSUES, 2021, 24 : 187 - 192
  • [30] Bringing 'the public' into health technology assessment and coverage policy decisions: From principles to practice
    Abelson, Julia
    Giacomini, Mita
    Lehoux, Pascale
    Gauvin, Francois-Pieffe
    HEALTH POLICY, 2007, 82 (01) : 37 - 50